Jazz Pharmaceuticals Agrees to Buy Celator for About $1.5 Billion

Jazz Pharmaceuticals agreed to buy Celator Pharmaceuticals in a roughly $1.5 billion deal that represents a huge premium for a company with a promising leukemia drug but no revenue.

from WSJ.com: US Business http://ift.tt/1Y0Fw8Z
via IFTTT